title: Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates.
abstract: A highly purified saponin from Q. saponaria (QS-21) was tested in juvenile rhesus macaques for adjuvant activity and toxicity. The QS-21 was tested alone or as part of an experimental subunit HIV-1 vaccine containing a truncated recombinant HIV-1 envelope protein (gp160D) adsorbed to alum. Antibody responses were measured using ELISA and cell-mediated immunity was measured using cellular proliferation assays. Potential toxicity was monitored by standard clinical pathology testing using peripheral blood and urine samples. No toxic effects were observed, even after the administration of the experimental vaccines three times at monthly intervals. The QS-21 saponin adjuvant enhanced total antibody production levels by greater than 100-fold and broadened the specificity of the response so that additional epitopes were recognized, when compared with alum-adsorbed HIV-1 gp160D formulation. Low-level, antigen-specific proliferative responses to HIV-1 recombinant gp160 were induced by either vaccine formulation. Proliferative responses were induced by a sham challenge with soluble recombinant HIV-1 gp160 for all of the animals that had been vaccinated. However, those that received the HIV-complete vaccine formulation containing QS-21 responded significantly better. These data demonstrated that the QS-21 adjuvant augmented both antibody responses and cell-mediated immunity and established immunological memory. The potent adjuvant activity and lack of toxicity suggest that this adjuvant should be safe and effective for use in HIV-1 vaccines.
authors: Cambridge Biotech Corporation, Worcester, MA 01605.
authors: M J
authors: MJ
authors: Newman
authors: J Y
authors: JY
authors: Wu
authors: R T
authors: RT
authors: Coughlin
authors: C I
authors: CI
authors: Murphy
authors: J R
authors: JR
authors: Seals
authors: M S
authors: MS
authors: Wyand
authors: C R
authors: CR
authors: Kensil
mesh_terms: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000818:Animals; D015686:Gene Products, env / Q000276:immunology*; D015483:HIV Antibodies / Q000096:biosynthesis; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000276:immunology*; D008213:Lymphocyte Activation; D008253:Macaca mulatta / Q000276:immunology; D008297:Male; D011498:Protein Precursors / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D012503:Saponins / Q000276:immunology*; D014614:Vaccines, Synthetic
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015686:Gene Products, env; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D011994:Recombinant Proteins; D012503:Saponins; D014614:Vaccines, Synthetic; C078785:saponin QA-21V1